Loading
Trials recruiting now, the landmark trials, the trials held by this cancer's subtypes, the key papers and what they mean, the latest literature, and the milestones year by year.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
3 trials on record are attached to one of the types below rather than to Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) itself. They are grouped by the type that holds them, so someone still working out which type they have can see the whole field from here.
One cancer page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
The regimen that made extranodal NK/T-cell lymphoma treatable. The usual explanation is that asparaginase is not a substrate of the P-glycoprotein pump this tumour expresses, which would explain why it works where anthracycline-based regimens do not; that mechanism is widely repeated but has been contradicted by at least one series.
The Japanese standard regimen for aggressive adult T-cell leukaemia/lymphoma rests on this trial. Three-year overall survival of 24 per cent with the better arm is the plainest statement of how much room remains, and is why allogeneic transplantation, mogamulizumab and antiviral approaches have all been pursued since.
The seroepidemiology that tied a virus to a cancer across a population rather than in one patient. It is the reason blood donations are screened for human T-lymphotropic virus type 1 in Japan and elsewhere, and the reason breastfeeding advice is part of cancer prevention in endemic regions.
The first human retrovirus, and the start of the line of work that identified HIV three years later. For lymphoma it means that adult T-cell leukaemia/lymphoma has a known, transmissible, preventable cause, and that screening blood donors and advising on breastfeeding in endemic areas are cancer prevention measures.
Query for this cancer: (TITLE:"Peripheral T-cell lymphomas" OR ABSTRACT:"Peripheral T-cell lymphomas" OR TITLE:"including cutaneous T-cell lymphoma" OR ABSTRACT:"including cutaneous T-cell lymphoma" OR TITLE:"PTCL" OR ABSTRACT:"PTCL" OR TITLE:"CTCL" OR ABSTRACT:"CTCL" OR TITLE:"Mycosis fungoides" OR ABSTRACT:"Mycosis fungoides" OR TITLE:"Anaplastic large-cell lymphoma" OR ABSTRACT:"Anaplastic large-cell lymphoma") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), not a curated reading list.
NPM-ALK identified by Morris et al.; ALK-positive ALCL becomes the good-prognosis PTCL.
First drugs specifically for relapsed PTCL.
Brentuximab-CHP improves OS over CHOP; mogamulizumab approved for MF/Sézary (MAVORIC).
Confirmatory Ro-CHOP trial negative.